Trilawil is a prescription medicine containing trientine tetrahydrochloride (also called trientine), a copper chelator indicated in the treatment of Wilson’s disease when clinically appropriate. As a healthcare professional resource, this page aligns Trilawil with Laurus Trientine search language used for the same Laurus trientine program; the active ingredient and monitoring principles are unchanged. Therapy reduces pathologic copper stores through urinary excretion of copper complexes and requires structured follow-up of hepatic, hematologic, and neurologic status. Counsel patients on empty-stomach dosing, separation from iron/zinc and antacids, and urgent review for worsening jaundice, neuropsychiatric decline, or suspected non-adherence.
Wilson’s disease is an autosomal recessive disorder of biliary copper excretion; without treatment, copper accumulates in liver, brain, and other tissues. Early diagnosis and continuous therapy improve outcomes; stopping chelation risks fulminant hepatic failure and irreversible neurologic injury.
The treatment of Wilson’s disease is lifelong in most patients and combines a copper chelator such as trientine (trientine tetrahydrochloride in Trilawil) with dietary copper restriction and guideline-based monitoring. Clinicians titrate therapy using 24-hour urinary copper, estimated non-ceruloplasmin-bound copper, liver tests, and clinical neurology where relevant. Neurologic Wilson’s disease may need slower dose escalation to avoid paradoxical worsening; hepatic presentations may require hepatology-intensive care. Pregnancy, surgery, and drug–drug interactions require proactive plan updates. Laurus Trientine program materials can support patient education but must not replace local prescribing information.
A copper chelator binds excess copper for renal elimination; trientine is an alternative to D-penicillamine when intolerance or contraindications arise. Trilawil delivers trientine tetrahydrochloride with improved physicochemical stability versus older salts, supporting predictable supply chains in practice. Monitor for iron deficiency (trientine can chelate iron), hypersensitivity, and gastrointestinal intolerance. Concomitant zinc maintenance regimens, if used, must be separated per protocol to avoid absorption interference. Document baseline and serial labs; coordinate with dietitians for low-copper diet reinforcement in Wilson’s disease care.
Trientine denotes the chelating molecule; trientine tetrahydrochloride is the four-hydrochloride salt formulated as Trilawil capsules. Prescribe by salt, strength, and administration rules—typically 1 hour before or 2 hours after meals. Interaction review should include iron, zinc, antacids, and other metal-containing products. For neurologically affected patients, document examination milestones and consider multidisciplinary rehab. Use consistent terminology with patients: brand (Trilawil), generic (trientine), and manufacturer shorthand (Laurus Trientine) may appear interchangeably in searches.
Laurus Trientine is branding language for Laurus’ trientine tetrahydrochloride offering—marketed as Trilawil—for Wilson’s disease. It signals manufacturer medical information, distribution, and access pathways rather than a separate pharmacologic class. HCPs should ensure patients receive counseling on lifelong therapy, emergency symptoms, and medication possession. Report adverse events per local pharmacovigilance requirements. Align communication with the caregiver site where appropriate so families receive consistent instructions on copper chelator timing and monitoring.
Wilson's disease is an inherited disorder of copper metabolism caused by mutations in the ATP7B gene. This gene produces a protein responsible for removing excess copper from the liver into bile for elimination from the body. When this protein is deficient or non-functional, copper accumulates in the liver and eventually spreads to other organs, particularly the brain and corneas of the eyes.
Wilson's disease typically presents between ages 5 and 35, though it can occur at any age. Symptoms vary widely depending on which organs are affected:
Hepatic (Liver) Manifestations: Elevated liver enzymes (often the first sign), fatty liver disease, acute hepatitis, chronic hepatitis, cirrhosis, acute liver failure.
Neurological Manifestations: Tremors (especially “wing-beating” tremor), dystonia (involuntary muscle contractions), difficulty speaking (dysarthria), difficulty swallowing (dysphagia), coordination problems (ataxia), Parkinsonian symptoms.
Psychiatric Manifestations: Depression, anxiety, personality changes, psychosis, cognitive impairment.
Ophthalmologic Manifestations: Kayser-Fleischer rings (golden-brown rings around the cornea, highly characteristic of Wilson's disease), sunflower cataracts.
Other Manifestations: Hemolytic anemia, kidney problems, bone and joint problems, heart problems (rare).
Trilawil contains trientine tetrahydrochloride, which belongs to a class of medications called copper chelators. The term “chelation” comes from the Greek word for “claw,” referring to how these molecules bind to metal ions.
Zinc Therapy: Zinc salts work differently than chelators — they block copper absorption from the intestines and are often used for maintenance therapy after initial chelation, or in presymptomatic patients.
Trilawil is indicated for:
Trientine hydrochloride was first approved by the U.S. FDA as an alternative copper chelating agent for Wilson's disease in patients intolerant to D-penicillamine. Trilawil contains the advanced formulation trientine tetrahydrochloride (TETA-4HCl), which was developed to address stability and adherence challenges of earlier trientine formulations. TETA-4HCl has received regulatory approval and has an orphan drug designation given the rare nature of Wilson's disease (affecting approximately 1 in 30,000 people worldwide).
Trientine tetrahydrochloride is clinically proven to reduce copper levels through a dual mechanism — systemic chelation via urinary excretion and enhanced metallothionein synthesis reducing intestinal copper absorption. The Phase III CHELATE trial (Lancet Gastroenterology and Hepatology, 2022) enrolled 53 adult subjects with clinically stable Wilson disease (Leipzig score ≥4) and demonstrated that more patients on trientine tetrahydrochloride achieved the pre-specified composite endpoint of non-ceruloplasmin-bound copper and 24-hour urinary copper excretion within therapeutic target ranges. Improvements in liver function tests (ALT, AST, bilirubin) and neurological symptoms were also observed.
Clinical studies demonstrate that continuous trientine therapy produces long-term remission in Wilson disease patients intolerant to D-penicillamine. Long-term outcomes include prevention of liver transplantation, stabilisation or improvement of neurological symptoms, and maintenance of safe copper levels. Trilawil begins lowering copper levels within weeks, with noticeable clinical improvements typically seen after several months of continuous therapy as body copper gradually normalises.
The CHELATE phase III trial (Schilsky et al., Lancet Gastroenterol Hepatol, 2022) directly compared trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease. Trientine tetrahydrochloride demonstrated non-inferiority to penicillamine in maintaining copper control, while offering a significantly better tolerability profile. D-penicillamine carries a conditional boxed warning due to serious adverse reactions, with up to 30% of patients experiencing adverse events necessitating discontinuation. In contrast, trientine is nonimmunogenic with a better overall safety profile.
Trilawil (trientine tetrahydrochloride) has a well-established superior safety profile compared to D-penicillamine. It is nonimmunogenic, with fewer allergic and dermatological reactions, lower risk of bone marrow suppression, reduced nephrotoxicity, and a lower likelihood of causing paradoxical neurological worsening at treatment initiation. Most common adverse reactions (>5%) are abdominal pain, change of bowel habits, rash, alopecia, and mood swings — generally mild and manageable.
Key published references: (1) Schilsky et al. Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol 2022. https://doi.org/10.1016/S2468-1253(22)00270-9 | (2) Woimant et al. Efficacy and Safety of Two Salts of Trientine in the Treatment of Wilson's Disease. J. Clin. Med. 2022, 11, 3975. | (3) Kamlin et al. Trientine Tetrahydrochloride, From Bench to Bedside: A Narrative Review. Drugs (2024) 84:1509–1518. | (4) Weiss et al. Comparison of the Pharmacokinetic Profiles of Trientine Tetrahydrochloride and Trientine Dihydrochloride in Healthy Subjects. Eur J Drug Metab Pharmacokinet. 2021 Sep;46(5):665-675.
Standard dosing is 20 mg/kg/day in 2–3 divided doses (maximum 2 g/day).
Adults (≥13 years): 750 to 1,250 mg of Trientine Tetrahydrochloride orally, in divided doses given 2, 3, or 4 times daily; maximum dose 2,000 mg/day.
Children (≤12 years): 500 to 750 mg orally in divided doses given 2, 3, or 4 times daily; maximum dose 1,500 mg/day.
All doses should be administered 1 hour before or 2 hours after meals for optimal absorption. Doses should be adjusted based on urinary copper excretion and clinical response; lower maintenance doses may be used after initial de-coppering.
Available Strengths: Trientine Tetrahydrochloride 333 mg hard capsules — available in bottles of 100 capsules (MRP: ₹18,749 per bottle, as of November 2025). For purchase, call Laurus Rare Diseases at 7337585050.
Based on urinary copper excretion and clinical response; lower maintenance doses may be used after initial treatment.
Required Monitoring Parameters:
Monitoring Frequency: Initial treatment every 2–4 weeks until stabilised; maintenance every 3–6 months; more frequent if complications or poor adherence.
Avoid concomitant administration with:
Trilawil should not be used in patients with known hypersensitivity to trientine or any component of the formulation. It should be used with caution in patients with pre-existing iron deficiency (trientine can chelate iron in addition to copper). If a hypersensitivity reaction such as rash occurs, discontinuation should be considered. Do not administer concomitantly with iron or zinc supplements, antacids containing aluminium or magnesium, or other copper-chelating agents unless specifically directed by a specialist.
Wilson's disease requires lifelong treatment. The main therapeutic strategies include:
1. Copper Chelators (Remove excess copper):
2. Zinc Salts (Block copper absorption): Zinc acetate or zinc sulfate; used for maintenance therapy or presymptomatic patients; can be combined with chelators; slower onset of action than chelators.
3. Liver Transplantation: Reserved for acute liver failure or decompensated cirrhosis not responding to medical therapy; curative for hepatic manifestations; may improve neurological symptoms over time.
4. Dietary Modifications: Avoid copper-rich foods (shellfish, nuts, chocolate, mushrooms, liver); check copper content of drinking water; use water filters if necessary.
Treatment Selection Guidelines:
For information on pricing, availability, and affordability support for Trilawil (Trientine Tetrahydrochloride 333 mg capsules), contact Laurus Rare Diseases directly at customer care number 7337585050 or visit www.laurusrarediseases.com/trilawil-healthcare.html. Patients are encouraged to speak with their treating physician or hospital pharmacist about available support schemes. Government-run rare disease programs and insurance schemes such as CGHS and state health missions in India may cover treatment costs for eligible patients with Wilson's disease. Patients can seek guidance on insurance navigation through ORDI (www.ordi.in).
Trilawil is the brand name of trientine tetrahydrochloride (TETA-4HCl) 333 mg capsules manufactured and marketed in India by Laurus Rare Diseases. Trientine is the active ingredient — a copper chelating agent used to treat Wilson's disease. The distinction matters because Trilawil uses the tetrahydrochloride salt form, which was specifically developed to address the stability challenges of earlier trientine dihydrochloride formulations. TETA-4HCl neutralises all four reactive amine groups, resulting in a more chemically stable molecule with improved shelf-life and consistent absorption. In summary: trientine is the drug; trientine tetrahydrochloride is the advanced salt form; and Trilawil is the Laurus Rare Diseases brand name.
Yes. Trilawil and Laurus Trientine refer to the same trientine tetrahydrochloride 333 mg capsules from Laurus Rare Diseases (Laurus Labs India). The official trade name is Trilawil; “Laurus Trientine” is common in search and internal program naming, not a different active ingredient.
Clinicians should document prescriptions using the approved brand and strength, counsel on empty-stomach administration and supplement separation, and apply the same monitoring plan for Wilson’s disease regardless of which label the patient recalls. Medical information: 7337585050 or www.laurusrarediseases.com/trilawil-healthcare.html.
Trientine tetrahydrochloride acts as a systemic copper chelator: trientine binds free copper to form soluble complexes cleared in urine, lowering total body copper in Wilson’s disease. A second component is reduced intestinal copper uptake related to increased metallothionein, complementing dietary copper control.
Clinical effect depends on adherence, correct timing relative to meals, and avoidance of iron, zinc, and antacids that interfere with absorption. Titrate using 24-hour urinary copper and non-ceruloplasmin-bound copper alongside hepatic and neurologic assessment. In the treatment of Wilson’s disease, do not equate biochemical response with permission to stop therapy—relapse can be rapid and severe.
No. You must never stop taking Trilawil without consulting your doctor, even if you feel completely well. Wilson's disease is not curable — it is a lifelong genetic condition that requires continuous treatment. Stopping medication, even briefly, can lead to rapid re-accumulation of copper in the liver and brain, potentially causing sudden and severe liver failure, neurological deterioration, or psychiatric symptoms. Many patients have experienced life-threatening relapses after self-discontinuing treatment. Feeling better is a sign that Trilawil is working, not a reason to stop. Always follow your healthcare provider's instructions and never adjust your dose or stop treatment without medical guidance.
A copper chelator is a medication that chemically “grabs” excess copper in the body and helps remove it. The word chelation comes from the Greek word for claw — describing how the drug molecule wraps around and locks onto copper ions, forming a stable complex. This complex is water-soluble and can be safely filtered out by the kidneys and excreted in urine. In Wilson's disease, the body cannot remove excess copper on its own because of a defective ATP7B gene. Trilawil (trientine tetrahydrochloride) acts as the body's substitute removal system — continuously clearing copper before it can build up to toxic levels in the liver, brain, and other organs. Think of it as a daily clean-up that keeps copper levels safe.
Both Trilawil (trientine tetrahydrochloride) and D-penicillamine are effective copper chelators for Wilson's disease, but they differ significantly in tolerability and safety. D-penicillamine has a conditional boxed warning due to serious adverse reactions, and up to 30% of patients experience adverse events severe enough to require discontinuation. It can also cause paradoxical neurological worsening when first started, bone marrow suppression, kidney damage, and hypersensitivity reactions. Trilawil is nonimmunogenic, has a much better safety profile, and is particularly preferred for patients with neurological symptoms or those who cannot tolerate penicillamine. The Phase III CHELATE trial demonstrated that trientine tetrahydrochloride is non-inferior to penicillamine in maintaining copper control while being significantly better tolerated. The choice between the two depends on individual patient factors — your specialist will recommend the most appropriate option for your specific situation.
Wilson's disease must not go untreated during pregnancy, as uncontrolled copper accumulation poses serious risks to both mother and baby, including liver failure and miscarriage. Trilawil should be continued during pregnancy only if clearly needed and under close medical supervision. Trientine is generally considered safer than D-penicillamine during pregnancy. Your physician may recommend a dose reduction during pregnancy — typically to the minimum effective dose — since some copper is required for foetal development. It is not currently known whether trientine passes into breast milk, so breastfeeding decisions should be made in consultation with your physician. Never stop treatment during pregnancy without medical guidance.
For more information about Trilawil or to discuss whether this medication is right for you, consult your healthcare provider or geneticist specialist. This information is for educational purposes only and does not replace professional medical advice.
This information is for educational purposes only and does not replace professional medical advice. Trilawil is a prescription medication that should only be used under medical supervision.
Disclaimer
Healthcare Professional
Healthcare Professional
